SCHEMBL9101707

SCHEMBL9101707

O=C1CCC(c2c[nH]c3ccncc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 5/20 0.41
HTR2C P28335 2/20 0.41
ADRB2 P07550 1/20 0.41
CCR2 P41597 3/20 0.40
HTR6 P50406 2/20 0.40
IKBKB O14920 1/20 0.39
KDM4E B2RXH2 1/20 0.37
BRD4 O60885 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
CREBBP Q92793 1/20 0.37
HSD11B1 P28845 1/20 0.36
PARP1 P09874 1/20 0.36
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
THPO P40225 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774187 0.82 HTR2C (0.62) CTSSHTR2CADRB2CCR2HTR6
SCHEMBL628780 0.78 HTR2C (0.66) HTR2CADRB2KDM4EBRD4ALDH1A1
SCHEMBL2064650 0.78 HTR1D (0.59) CTSSKDM4EHTR1DHTR1BCYP1A2
SCHEMBL18324777 0.76 KDM4E (0.69) CTSSCCR2IKBKBKDM4EBRD4
SCHEMBL18324773 0.76 CTSS (0.52) CTSSCCR2KDM4EBRD4ALDH1A1
Ethylene SCHEMBL7482134 0.76 HTR2C (0.62) HTR2CADRB2KDM4EBRD4ALDH1A1
SCHEMBL27933991 0.74 HTR6 (0.38) CTSSHTR2CADRB2CCR2HTR6
SCHEMBL2217699 0.73 SLC6A4 (0.56) HTR2CADRB2IKBKBALDH1A1HTR1D
SCHEMBL6633514 0.73 OPRL1 (0.56) IKBKBHSD11B1
SCHEMBL6634183 0.73 SLC6A4 (0.56) HTR6IKBKBHTR1DHTR1BCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921559-B2 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 JANSSEN PHARMACEUTICA NV (BE) 2014-12-30 US disclosed
EP-2646429-B1 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA NV (BE) 2014-10-15 EP disclosed
EP-2646429-A1 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 Janssen Pharmaceutica, N.V. (BE) 2013-10-09 EP disclosed
WO-2012075115-A1 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA NV (BE) 2012-06-07 WO disclosed
US-20120142733-A1 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 JANSSEN PHARMACEUTICA N.V. (BE) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142733-A1 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 CCR2, CCR5, CCR1 CTSS 1106/4885HTR2C 701/4885ADRB2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.